Dyslipidaemia Therapeutics Market Trends Discussed by Black Swan Analysis in Its Topical Report Published at MarketPublishers.com

20 Apr 2017 • by Natalie Aster

LONDON – Dyslipidaemia is the elevation of total plasma cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride (TG) levels, or a decrease in high-density lipoprotein (HDL) cholesterol concentration which contributes to the development of atherosclerotic disease.

There are primary (single or multiple gene mutations) or secondary disease causes. The key secondary cause in the developed countries comprise a sedentary life style with excessive food intake of saturated and trans fats, and cholesterol. Other common secondary causes include diabetes, alcohol overindulgence, chronic kidney disease, hypothyroidism, certain cholestatic liver diseases, as well as specific drugs like β-blockers, thiazides, retinoids, cyclosporine, tacrolimus, highly active antiretroviral agents, estrogen and progestins, and glucocorticoids

Dyslipidemia is diagnosed by measuring serum lipids within the blood, such as total cholesterol (TC), HDL cholesterol, TGs, and LDL cholesterol.

Treatment options comprise dietary modification, exercises, and various anticholesterol drugs.

Topical research study “Dyslipidaemia Forecast in 12 Major Markets 2017-2027” worked out by Black Swan Analysis provides an insightful, detailed analysis of the dyslipidaemia marketplace on a global level.

It provides the present-day prevalent population for dyslipidaemia across 12 leading markets such as the USA, France, Canada, Spain, Russia, Germany, Italy, the UK, Brazil, Japan, China and India; with data being broken down by gender and 5-year age cohort.

The research gives a detailed review of the risk factors of the disease, diagnosis and prognosis of dyslipidaemia, in tandem with specific variations based on geographical region and ethnicity. 

It quantifies a number of the main symptoms and co-morbidities of the disease, as well as provides overall figures for dyslipidaemia prevalence rates. The subpopulations within dyslipidaemia in the key countries are analysed and forecasted from 2017 to 2027.

Reasons to Buy:

  • Get trustworthy data on dyslipidaemia patient numbers globally to target the development of novel products, pricing strategies as well as launch plans.
  • Discover information on the prevalence rates of the subdivided disease types and patient segments with high potential.
  • Get insights into the clinical trials country-wise.
  • Understand how certain co-morbid conditions influence dyslipidaemia prevalent population.
  • Know what sub-populations within dyslipidaemia require treatment.
  • Be informed about the markets with the majority of dyslipidaemia patients.

More insightful market research reports by our partner are available at its page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com